Familial Hypercholesterolemia: Genes and Beyond.
Warden BA, Fazio S, Shapiro MD.
Warden BA, et al.
2021 Oct 23. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–.
2021 Oct 23. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–.
PMID: 26844336
Free Books & Documents.
Review.
Novel therapeutics recently developed, include: inclisiran - a small interfering ribonucleic acid (siRNA)-based gene-silencing technology that inhibits PCSK9 production (approved in the European Union only thus far), bempedoic acid - an inhibitor of adenosine triphosphate (ATP)-c …
Novel therapeutics recently developed, include: inclisiran - a small interfering ribonucleic acid (siRNA)-based gene-silencing technology th …